Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results in twenty-nine patients

Most patients with erythrodermic cutaneous T-cell lymphoma (CTCL) have intense, generalized, refractory pruritus. In some large series the median survival was approximately 3 years. Our purpose was to review our experience with methotrexate in the treatment of 29 patients with erythrodermic CTCL obs...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 1996-04, Vol.34 (4), p.626-631
Main Authors: Zackheim, Herschel S., Kashani-Sabet, Mohammed, Hwang, Sam T.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - adverse effects
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Dermatitis, Exfoliative - drug therapy
Disease-Free Survival
Female
Follow-Up Studies
Humans
Lymphoma, T-Cell, Cutaneous - drug therapy
Male
Medical sciences
Methotrexate - administration & dosage
Methotrexate - adverse effects
Methotrexate - therapeutic use
Middle Aged
Neoplasm Staging
Pharmacology. Drug treatments
Pruritus - drug therapy
Remission Induction
Retrospective Studies
Skin Neoplasms - drug therapy
Survival Rate
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most patients with erythrodermic cutaneous T-cell lymphoma (CTCL) have intense, generalized, refractory pruritus. In some large series the median survival was approximately 3 years. Our purpose was to review our experience with methotrexate in the treatment of 29 patients with erythrodermic CTCL observed for up to 129 months. This is a retrospective study. Data are presented in terms of response rates, freedom from treatment failure, and overall survival. Twelve patients (41%) achieved complete remission, and five (17%) achieved partial remission for a total response rate of 58%. The median freedom from treatment failure was 31 months, and the median survival was 8.4 years. Side effects caused treatment failure in only two patients. Low-dose methotrexate is a valuable first-line treatment for the majority of patients with early to intermediate-stage erythrodermic CTCL.
ISSN:0190-9622
1097-6787
DOI:10.1016/S0190-9622(96)80062-4